Nemaura Medical Inc.: Nasdaq/NYSE listing notice — Nemaura Medical accepts Nasdaq delisting, moves to OTC Markets; suspension Jan 5, 2024

Nemaura Medical Inc.

Board and management strategically decided to accept Nasdaq's determination to delist the company.
Received written notice from Nasdaq Hearings Panel on January 3, 2024, confirming delisting.
Trading on Nasdaq suspended effective January 5, 2024; company will not request review.
Shares expected to trade on OTC Markets following suspension.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Nemaura Medical Inc. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

January 3, 2024, Nemaura Medical Inc. (the “Company”) issued a press release providing a crucial update regarding recent decisions that will impact the Company's listing status on The Nasdaq Capital Market and its broader strategic direction. Among other things, the press release indicated that, after thorough analysis, the Company’s Board of Directors and its management team have made the strategic decision to accept Nasdaq’s determination to delist the Company and move to the OTC Markets. Subsequently, on January 3, 2024, the Company received written notice from Nasdaq indicating that the Na

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001079973-24-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.